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Abstract
Objectives: To conduct a systematic review for the evidence supporting or disproving the reality of parenteral
nutrition- antiepileptic drugs interaction, especially with respect to the plasma protein-binding of the drug.
Methods: The articles related to the topic were identified through Medline and PubMed search (1968-Feburary
2010) for English language on the interaction between parenteral nutrition and antiepileptic drugs; the search
terms used were anti-epileptic drugs, parenteral nutrition, and/or interaction, and/or in vitro. The search looked for
prospective randomized and nonrandomized controlled studies; prospective nonrandomized uncontrolled studies;
retrospective studies; case reports; and in vitro studies. Full text of the articles were then traced from the Universiti
Sains Malaysia (USM) library subscribed databases, including Wiley-Blackwell Library, Cochrane Library, EBSCOHost,
OVID, ScienceDirect, SAGE Premier, Scopus, SpringerLINK, and Wiley InterScience. The articles from journals not
listed by USM library were traced through inter library loan.
Results: There were interactions between parenteral nutrition and drugs, including antiepileptics. Several
guidelines were designed for the management of illnesses such as traumatic brain injuries or cancer patients,
involving the use of parenteral nutrition and antiepileptics. Moreover, many studies demonstrated the in vitro and
in vivo parenteral nutrition -drugs interactions, especially with antiepileptics.
Conclusions: There was no evidence supporting the existence of parenteral nutrition-antiepileptic drugs
interaction. The issue has not been studied in formal researches, but several case reports and anecdotes
demonstrate this drug-nutrition interaction. However, alteration in the drug-free fraction result from parenteral
nutrition-drug (i.e. antiepileptics) interactions may necessitate scrupulous reassessment of drug dosages in patients
receiving these therapies. This reassessment may be particularly imperative in certain clinical situations
characterized by hypoalbuminemia (e.g., burn patients).
Introduction
In the past, many efforts have been made to supply nutri-
ents intravenously through cannulation of peripheral
veins. However, administration of different feeding solu-
tions like milk, salted water and glucose were associated
with thrombophlebitis or fluid overload [1]. In 1968,
Dudrick and his colleagues administered a nutrition solu-
tion through the superior vena cava, enabling the adminis-
tration of a small volume of nutrition solution with high
nutrient concentrations [2]. T h ep r a c t i c eo fi n t r a v e n o u s
feeding was then utilised to nourish an infant for more
than 6 weeks. Subsequently, many adult and paediatric
patients with gastrointestinal abnormalities were sustained
by nutrition support via a central venous catheter [3,4].
A great advancement has been made in methods for IV
cannulation and IV nutrient liquids formulation during
the past four decades. Currently, the IV administration of
complex nutrient mixture is equated with parenteral nutri-
tion (PN) and has become a vital part of the health man-
agement for both outpatients and hospitalised patients
who are not able to eat or consume nutrients through the
gastrointestinal tract [1].
The parenteral nutrition technique can be applied to
all patients regardless of their gastrointestinal function
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troversial issues may be involved in the assessment of
beneficial effects gained from IV nutrition in certain
patients [5-9]. Malnutrition has been found to have
negative effects on the incidence of postoperative com-
plications, length of hospitalisation, and mortality
[10-20]. A patient’s nutritional status can be improved
and reinstated by both parenteral and enteral nutrition
[21-32]. Although previous studies have demonstrated a
positive effect of nutrition support on length of hospital
stay, morbidity, and mortality [8,18,28,33-36]. A meta-
analysis study has revealed that total parenteral nutrition
does not have an effect on the death rate of surgical
patients, but it may possibly decrease the complication
rate, particularly in malnourished patients [37]. Conse-
quently, clinicians must consider the general guidelines
and clinical judgments as the basis and structure for
deciding the suitability of nutrition support.
Several questions can be considered in deciding
whether nutrition support is clinically beneficial for a
given patient [38]:
￿ Does malnutrition exist?
￿ Will the malnutrition contribute to an increased
likelihood of mortality or morbidity, or decrease in
the response to other therapies?
￿ Is the existing malnutrition a consequence of star-
vation, altered metabolism, or a combination of
both?
￿ Will treating the malnutrition with either enteral
or parenteral nutrition result in an improvement in
nutritional status?
￿ Will an improvement in nutritional status affect
morbidity, response to therapy, or mortality?
￿ Considering the effect of nutrition support on
patient outcome, will the cost of providing nutrition
support outweigh the cost of not providing nutrition
support?
A number of aspects have to be considered when asses-
sing a patient’s suitability for nutrition support, including
the patient’s age, the existence of critical illness, the occur-
rence of malnutrition and its severity, and the importance
of nutrition support to the whole therapeutic management
plan [39]. The cornerstone that governs the decision on
which route of nutrition support should be utilised in a
certain patient is the functional capability of the gastroin-
testinal tract. Generally, the enteral route is more favoured
than the PN as it consistently meets the nutrition require-
ments [40]. However, PN should be used when nutrition
requirements cannot be met by enteral nutrition and
when the gastrointestinal tract is not functioning or
cannot be accessed. As with any therapy, patients should
be monitored and should undergo thorough routine
evaluations to assess the best route of nutrition support as
frequently as possible.
Many types of complications may be associated with
the use of PN, such as mechanical and septic complica-
tions related to intravenous catheters. These complica-
tions may be observed directly after placing of a central
venous catheter and may include intravascular and
extravascular malposition, hydrothorax, hemothorax,
brachial nerve plexus injury and pneumothorax [41-45].
Thrombosis is considered to be one of the late compli-
cations that may happen in the lumen of the intrave-
nous catheter and may also affect the blood vessel
around the catheter [41-47]. Contaminated IV fluid or
contamination of the catheter site may lead to septicae-
mia, which is considered to be a serious, life-threatening
complication [41-46,48-55]. In addition to the mechani-
cal and septic complications, various sorts of metabolic
complications may be associated with PN. The most fre-
quently reported abnormalities are hypokalaemia, hypo-
magnesaemia, hypophosphataemia and hyperglycaemia.
Routine monitoring of these serum electrolytes is very
important to identify any electrolyte disturbances and to
avoid any possible complications [56].
Improvement of pharmaceutical safety has been stu-
died in terms of stability and compatibility for total par-
enteral nutrition (TPN) admixture [57]. Parenteral drugs
should be given separately from TPN solutions. How-
ever, sometimes it is impossible to absolutely dedicate
the lumen to administration of TPN, particularly in ICU
and cancer patients. In such patients, the number of IV
drugs sometimes exceeds the number of available access
sites [58]. Although intravenous drug-drug incompatibil-
ity has been widely discussed [59], information relating
to drug-PN incompatibility is limited. The problem is
compounded by the huge variability in nutrition compo-
nents and concentrations; furthermore, there are differ-
ent ranges and concentrations of drugs that may be
used [58]. Even though PN plays a significant role in a
variety of cases, there are some potential interactions
that might occur with drugs administered concurrently
with PN. Therefore, the goal of this article was to per-
form a systematic review for the evidence supporting or
disproving the existence of PN- antiepileptic drugs
interaction, especially with respect to the plasma pro-
tein-binding of the drug.
The authors conducted Medline and PubMed search
from 1968 to February 2010 for English- language arti-
cles describing the interaction between PN and antiepi-
leptic drugs; the search terms used were anti-epileptic
d r u g s ,P N ,a n d / o ri n t e r a c t i o n ,a n d / o ri nv i t r o .T h e
search looked for prospective randomized and nonran-
domized controlled studies; prospective nonrandomized
uncontrolled studies; retrospective studies; case reports;
and in vitro studies. Full text of the articles were then
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subscribed databases, including Wiley-Blackwell Library,
Cochrane Library, EBSCOHost, OVID, ScienceDirect,
SAGE Premier, Scopus, SpringerLINK, and Wiley Inter-
Science. The articles from journals not listed by USM
library were traced through inter library loan.
Study designs
After performing the required search, a huge lacking of
the formal research evidence was found. So that, this
review will mostly depend on the use of anecdotes and
case reports to describe some of the pharmacokinetic
i s s u e s( m a i n l yp l a s m ap r o t e i nb i n d i n g )o ft h eu s ea n t i -
epileptic drugs and PN in critically ill patients.
Parenteral nutrition and anticonvulsants in traumatic
brain injury
Serious head injury is often followed by hypermetabo-
lism, hypercatabolism, and nitrogen loss [60,61]. Hyper-
metabolism is characterised by an increase in the levels
of catabolic hormones, especially cortisol, epinephrine,
norepinephrine, and glucagon. Hypermetabolism results
from an elevation in the level of catabolic hormones,
cytokines, and catecholamines, leading to increases in
the cardiac output, tachycardia, and mild hypertension.
Consequently, oxygen consumption and caloric require-
ment will be increased. A hypercatabolic state is the
consequence of amino acid mobilisation from skeletal
muscles, gluconeogenesis, increased nitrogen excretion,
loss of weight, and muscle wasting. In addition to the
skeletal muscles, visceral and circulating protein will
undergo proteolysis if aggressive nutritional support is
not provided [60,62]. Hypermetabolic and hypercatabolic
states can precipitate a condition of severe malnutrition
that leads to several complications, such as poor wound
healing, loss of body mass, immunosuppression, infec-
tion, and multiple organ failure [60,63]. Therefore,
nutritional support is mainly given to ensure the
required calories and proteins and to achieve a positive
nitrogen balance [63]. However, a positive nitrogen bal-
ance may not be reached for 2 to 3 weeks after injury,
even with aggressive nutritional support [60,64]. Nutri-
tional therapy is recommended by the Guidelines for
the Management of Severe Head Injury, which state that
nutrition support should start within 72 hours of injury
and with complete caloric replacement should be
achieved within 7 days [65].
Total parenteral nutrition provides early feeding if ent-
eral nutrition is not accessible or enteral feeding is not
feasible due to gastrointestinal malfunction. Total par-
enteral nutrition provides a steadier nutritional intake
and causes less diarrhoea than enteral nutrition [63].
Seizure is one of the most common posttraumatic
complications in patients with a recent head or brain
injury [66]. Jennett confirmed that the severity of a
brain injury can be used to estimate the probability of
early (within 7 days of injury) and late (after 7 days) risk
of seizures [67]. Annegers and colleagues have demon-
strated that a small increase in the risk of epilepsy may
be noted in subsequent years with mild (loss of con-
sciousness or amnesia for less than 30 minutes) and
moderate brain injuries (loss of consciousness, amnesia
for 30 minutes to 24 hours, or skull fracture). In
addition, a significantly increased risk of epilepsy is asso-
ciated with more severe brain injuries (loss of conscious-
ness, amnesia lasting for more than 24 hours, subdural
haematoma, or brain contusion) over the next 10 years
[68]. A systematic review of ten randomised controlled
trials revealed consistent evidence regarding the early
management with anticonvulsant drugs after head
injury. Phenytoin is the gold standard; however, pheno-
barbital and carbamazepine also reduced the relative
risk of early seizures [69]. Moreover, valproic acid was
suggested as an alternative agent for posttraumatic sei-
zure prophylaxis; however, patients receiving valproic
acid had a slightly higher mortality rate than those
receiving other antiepileptic drugs [70].
Parenteral nutrition and anticonvulsants in cancer
patients
Many review articles and meta-analysis studies have been
published to evaluate the effects of nutritional support in
cancer patients. In this sequence, a consensus has been
made to create standards for nutritional support in can-
cer patients [71]. Klein et al. utilised 28 randomised con-
trolled trials to evaluate the use of PN in cancer patients.
They concluded that the use of PN in patients with can-
cer of the gastrointestinal tract is justified. Although the
risk of infection increased in patients receiving both PN
and chemotherapy, the authors did not rule out the
potential benefit of PN in cancer patients treated with
radiotherapy and chemotherapy [72]. Another review
article including 12 randomised controlled trials was
published by the American College of Physicians. The
aim of this review was to predict the effect of PN on sur-
vival and tumour response rate in patients undergoing
chemotherapy. The findings of the pool analysis revealed
t h a tt h et u m o u rr e s p o n s er a t ew a sn o ti m p r o v e db yP N
and that there was no significant difference between the
control patients and those who received PN in terms of
the survival rate [73]. The American Society for Parent-
eral and Enteral Nutrition (ASPEN) recommended the
following practice guidelines [74]:
￿ Enteral and parenteral nutrition may have positive
effects in some severely malnourished cancer
patients or those who are unable to take adequate
oral nutrition for more than one week. Patients
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port, if possible, in concurrence with the start of
oncologic therapy.
￿ Nutritional support is not routinely recommended
for mildly malnourished or well-nourished patients
and those who are able to receive adequate nutrition
via oral intake, even if they are undergoing che-
motherapy, radiotherapy, or surgery.
￿ Total parenteral nutrition may have an invaluable
effect in the management of patients with advanced
cancer that are identified as unresponsive to radia-
tion therapy or chemotherapy.
Furthermore, a prospective evaluation of quality of
life in one hundred forty-six patients with head and
neck cancer was reported [75]. The results revealed
that nutrition support should be applied in cancer
patient because its positive effects can improve the
overall quality of life. In addition to nutritional
support, anticonvulsant drugs may be incorporated in
the treatment of cancer patients because seizure is a
common neurological complication in patients with
primary brain tumours and brain metastases [76,77]. A
large discrepancy in seizure frequency was noted
between patients with different primary brain tumours
and patients with cerebral metastases from various pri-
mary tumours (Table 1) [77].
The majority of brain tumour patients need chronic
treatment with antiepileptic drugs because seizures are
common in this population of patients. Sometimes, pro-
phylactic use and acute treatment with antiepileptic
drugs might be necessary [77]. Actually, clinicians follow
general guidelines for the acute therapeutic management
of seizures in patients with both epilepsy and brain
tumours, including intravenous benzodiazepines, val-
proic acid, and levetiracetam, followed by phenytoin and
then barbiturate if necessary [78]. Older generations of
antiepileptic drugs (phenytoin, carbamazepine, and
oxcarbazepine) are hepatically metabolised and induce
cytochrome P450, which can reduce the efficacy of che-
motherapeutic agents. New generations of antiepileptic
drugs might be more convenient for the chronic treat-
ment of seizures in cancer patients in relation to the
induction of liver enzyme [77].
Valproic acid is a broad-spectrum antiepileptic drug
t h a th a sb e e nc o n s i d e r e da sas a f ea n dp o t e n td r u gf o r
many decades. Recently, many studies have shown that
valproic acid has some anticancer properties [79-81].
However, further studies are required to evaluate the effi-
cacy and safety of valproic acid; not only as an antiepilep-
tic drug, but also as a potential anticancer drug in
patients with brain tumours [77]. Although prophylactic
administration of anticonvulsant drugs is evidence-based
in some circumstances, it is not recommended and might
not be effective at preventing the first seizure [76,77].
Systematic categorisation of drug-nutrient interactions
Interactions between drugs and nutrients frequently
occur and might have a negative impact on the patient’s
clinical outcome [82]. These interactions became more
relevant with the dramatic development of nutrition
support and with the increased use of multiple medica-
tions. Identification of clinically important interactions
can help in avoiding or early management of adverse
effects resulting from drug-nutrient interactions. This
point was emphasised by the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO)
through its standards that encourage clinicians to moni-
tor any potential interactions between drugs and nutri-
ents [83]. Based on the current information required for
recognition and suitable management of drug-nutrient
interactions in patients receiving parenteral and enteral
nutrition, drug-nutrient interactions were sorted into
four types [84]:
￿ Ex vivo biopharmaceutical inactivations
￿ Interactions affecting the absorption phase
Table 1 Seizure frequency within different primary brain
tumours and within cerebral metastases from various
primary tumours
Cerebral tumour Frequency
Primary brain tumours
Malignant Glioma 50%
Low Grade Glioma 75%
Dysembryoblastic neuroepithelial 100%
Ganglioglioma 90%
PCNSL 10%
Cerebral metastases
Melanoma 67%
Lung 39%
Unknown histology 25%
Gastrointestinal tumours 21%
Breast cancer 16%
Non Hodgkin Lymphoma 15%
Gynaecological 11%
Prostate cancer 0%
Others 12%
Total 20-40%
Other neurooncological disease
Neoplastic Meningitis 10%
Oncological patients in general 14%
From Oberndorfer and Grisold (2008) [77] with permission of the author and
the publisher.
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dispositions
￿ Interactions affecting elimination/clearance
Ex vivo biopharmaceutical inactivations
The contact between drug molecules and nutritional
constituents that leads to physical or biochemical reac-
tions may occur through ex vivo biopharmaceutical
interactions. These interactions typically happen outside
the body, either in the delivery system (e.g., infusion
bags or infusion tubings) or during the compounding
process. Several examples are available for this type of
interaction, such as the physical incompatibility between
PN fluid and intravenous drugs, the hydrolysis reaction
that results from the direct mixing of oral liquid drugs
with enteral feeding formula, and the destruction of fat
emulsion that occurs when a large quantity of heparin is
added into 3-in-1 parenteral nutrition formula. Crystals,
precipitates or other undissolvable intermediates may
result from these interactions as a final byproduct. Life-
threatening events (e.g., occlusion of blood vessels) may
occur from the systemic exposure of the patient to these
byproducts. On the other hand, physical incompatibility
with enteral nutrition usually does not cause life-threa-
tening conditions, but it may result in a decrease in the
therapeutic effect or poor nutritional improvement [84].
One of the common examples that can be seen is the
dramatic reduction in the phenytoin absorption when
given with enteral nutrition [85,86].
Absorption interactions
Absorption interactions can occur with drugs and nutri-
ents that are only taken or delivered orally or through
enteral feeding delivery systems. The oral bioavailability
of the active drug may increase or decrease as a result
of these interactions [84]. Absorption interactions can
be subclassified into the following three types: 1) presys-
temic metabolism (e.g., grape fruit juice with carbamaze-
pine) [87], 2) presystemic transport (e.g., vitamin E and
cyclosporine) [88], and 3) presystemic binding/com-
plexation (e.g., tetracycline binding to divalent cations in
the gastrointestinal tract) [89].
Interactions affecting systemic or physiologic dispositions
This type of interaction occurs after the drug molecule
or the nutritional constituent has reached the systemic
circulation. It might be observed as an alteration in
tissue distribution, systemic metabolism, or penetration
into a specific tissue. In some clinical situations, the
interaction between the drug and the nutrient element
may be mediated by cofactors or hormones [84]. One
example of this phenomenon is the reduction in the
anticoagulant effect of warfarin with a vitamin K-rich
diet [90]. Intravenous fat emulsions are supplementary
resources of vitamin K and have been correlated
with warfarin resistance when used in combination
with intravenous nutrition or as delivery system for
propofol [91].
Interactions affecting drug elimination or clearance
This type of interaction influences either hepatic meta-
bolism or renal elimination of the object agents via the
involvement of precipitant agents. Numerous pathways
may be involved, such as the antagonism, modulation,
or diminishment of renal or enterohepatic transporta-
tion [84]. High protein diets have been seen to enhance
the hepatic elimination of certain drugs like propranolol
[92]. The use of aminoglycosides in malnourished
patients may be considered as another example of these
interactions. Both the volume of distribution and the
extracellular fluid compartment may show a significant
expansion due to a decrease in the lean tissue mass.
Therefore, dosing adjustment of aminoglycosides in mal-
nourished patients must be matched with any alteration
in the volume of distribution in order to achieve the
appropriate therapeutic drug concentrations [93].
Nutrient-antiepileptic drugs interactions
Similar to haemoglobin, albumin undergoes an in vivo
non-enzymatic glycosylation; in fact, approximately
6-10% of the total serum albumin is glycosylated in
healthy adult. A group of investigators found that the
binding affinities for long chain fatty acid and bilirubin
were lower when the glycosylation of albumin was
increased [94]. Zimmerman et al. reported that an
increase in the concentration of free fatty acids in serum
led to an increase in the free fraction of valproic acid
[95]. Doucet et al. observed that phenytoin protein bind-
ing was significantly decreased in sera from diabetics,
but there was no correlation between the percentage of
binding and the concentration of glycated albumin [96].
Moreover, Dutkiewicz et al. demonstrated that in
hypercholesterolemia and in mixed hyperlipidemia, the
free phenytoin concentration was increased. This effect
was most likely correlated with the displacement of phe-
nytoin by free fatty acids [97,98]. Accordingly, the free
fatty acids from fat emulsions in TPN fluid could dis-
place phenytoin or other drugs from their albumin-
binding sites.
Previous studies have shown that drug binding to site
II of human serum albumin can be significantly altered
by L-tryptophan in amino acid fluids. Because phenytoin
can react with site II of human serum albumin [99],
these findings are substantially useful for evaluating the
pharmacokinetic and pharmacodynamic effects of
phenytoin or other therapeutic drugs in patients receiv-
ing TPN or a parenteral nutrition solution with amino
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toin concentration was reported in a 40-year-old man
who started TPN therapy concurrently with phenytoin;
the total phenytoin concentration subsequently
increased to the pre-TPN concentration following the
cessation of TPN therapy [101]. The competitive bind-
ing of selected therapeutic drugs to five PN formulas
and to human serum in vitro has been evaluated using
equilibrium dialysis. Phenytoin, phenobarbital, and val-
proic acid were found to be bound less in the presence
of PN than human serum (Table 2), suggesting that the
free fraction of these drugs might increase in vivo in the
presence of these fluids [102].
Alteration of plasma protein binding of antiepileptic
drugs
Several factors have been shown to alter the binding of
antiepileptic drugs to plasma protein, including hypoal-
buminaemia (patients with burns, old age, pregnancy,
AIDS etc.) [103,104]; patients with uraemia [105]; drug-
drug interactions; displacement of the drug from its
plasma protein binding by another drug [106,107]; and
patients with chronic liver disease [108].
In vitro and in vivo studies have been done to observe
the displacement of phenytoin from its protein-binding
site by antibiotics. The results showed that ceftriaxone,
sulfamethoxazole, and nafcillin could all displace pheny-
toin from serum protein carriers [109].
The effect of albumin and a-1-acid glycoprotein on
the binding of therapeutic drugs has been determined
by Bailey and Briggs. Their study showed that increasing
the concentration of a-1-acid glycoprotein will increase
t h ed e g r e eo fp h e n y t o i nb i n d i n gb y3 - f o l d ,w h e r e a s
decreasing albumin concentration will decrease the
binding by less than 1.2-fold. Phenobarbital and valproic
acid exhibited an elevation in their free level when albu-
min concentration was reduced. Ultimately, conditions
like acute inflammation that increase a-1-acid glycopro-
tein may result in a decrease in the free phenytoin
concentration which would not be significantly offset by
the decease of albumin levels [110].
Albumin binding sites
Pharmacokinetics are crucially directed by drug-protein
binding in the blood that involve transportation, meta-
bolism and elimination of many pharmaceutical agents.
This type of binding can also be a starting place for
drug-drug interactions [111-113]. Consequently, it is
important to have good knowledge about the type and
number of binding sites that a certain drug will interact
with on a given protein because this information allows
us to estimate how this agent will be influenced by
other substances.
Albumin is considered to be the most important
plasma protein that is involved in such interactions. The
warfarin-azapropazone site (Sudlow Site I) and the
indole-benzodiazepine site (Sudlow Site II) are the two
major albumin binding sites for drugs [114]. Additionally,
there are several minor binding sites on albumin for var-
ious drugs such as digitoxin and tamoxifen [115,116].
High performance affinity chromatography was used to
study the binding of phenytoin to albumin. This study
found that phenytoin can interact with albumin at the
warfarin, benzodiazepine, tamoxifen and digitoxin sites of
this protein (Figure 1) [99]. Dasgupta and Timmerman
have studied the in vitro phenytoin displacement from
protein binding by some non-steroidal anti-inflammatory
drugs in both normal and uremic sera. The results illu-
strated that free phenytoin levels were significantly
increased with ibuprofen in both normal and uremic sera
[117]. Due to the re-equilibrium phenomena, the in vivo
situation might be slightly different. The free phenytoin
concentration may not change; it is the free fraction that
changes. Ibuprofen-phenytoin interactions can be
predicted from their albumin binding sites. Kragh-
Hansen et al. showed that ibuprofen is a selective drug
probe for site II of human serum albumin [118].
Table 2 Differences in binding of some antiepileptic
drugs to parenteral nutrition fluids and to human serum
Drug Parenteral
nutrition
formulas
Fluid †
(μmol/L)
Serum
(μmol/L)
Average
Competitive
Binding
Difference ‡
Carbamazepine A 16.1 2.1 77%
B 16.9 1.7 82%
C 17.8 2.5 75%
D 16.9 2.1 78%
E 17.3 2.5 75%
Phenytoin A 32.4 88.7 -46%
B 35.0 80.6 -39%
C 34.1 74.8 -37%
D 31.7 67.9 -36%
E 31.7 68.3 -37%
Phenobarbital A 56.8 75.9 -14%
B 58.9 74.8 -12%
C 61.1 77.4 -12%
D 58.5 77.4 -14%
E 61.9 78.0 -12%
A 181.8 1290.2 -75%
Valproic acid B 194.0 1179.6 -72%
C 156.7 1061.6 -74%
D 127.0 993.2 -77%
E 207.6 998.1 -66%
†A = 4.5% Travasol_/25% dextrose; B = 4.5% Travasol_/10% dextrose;
C = 4.5% Travasol_/5% dextrose; D = 2.5% Travasol_/10% dextrose; E = 2.5%
Travasol_/5% dextrose. ‡100% × (Concentration in Fluid - Concentration in
Serum)/(Concentration in Fluid + Concentration in Serum).
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Many drugs bind to various plasma proteins (albumin &
a-1-acid glycoprotein). This protein binding can be low,
moderate or high (>80%). Some drugs, such as ethosuxi-
mide and lithium, don’t bind to any plasma proteins
[119]. Protein binding of most monitored therapeutic
drugs is shown in Table 3 [108]. Reversible equilibrium
and law of mass action govern the existence of drugs in
the peripheral circulation as free (unbound) and bound
to proteins. Only free drug can produce the pharmaco-
logical action by crossing the plasma membrane and
binding with the receptors [119]. In addition, the free
drug component can freely cross blood-CSF or blood
brain barriers [120]. In general, drugs that highly bind
plasma proteins are the most important candidates for
monitoring of free drug concentrations because varia-
tion in protein binding may produce a clinically note-
worthy effect in altering free drug concentrations.
Newer drugs such as mycophenolic acid, mofetil and
certain protease inhibitors are considered to be good
candidates for monitoring free drug concentrations.
However, free drug concentrations of the old generation
of antiepileptic drugs such as phenytoin, carbamazepine
and valproic acid are still the most requested by clini-
cians [108].
Old generation antiepileptic drugs
Traditional antiepileptic drugs such as valproic acid, car-
bamazepine and phenytoin are highly bound to protein.
The clinical usefulness of monitoring free concentra-
tions of those drugs has already been studied and docu-
mented. Furthermore, the external survey specimens of
the College of American Pathologists have also listed
the free anticonvulsant concentrations, and assay kits
for measurement of free concentrations of these drugs
are commercially available [108].
T h ep l a s m ap r o t e i nb i n d i n g of valproic acid ranges
from 90 to 95% and occurs mainly with albumin [121].
Because of the saturable binding phenomenon, valproic
acid shows vacillation in its protein binding within the
therapeutic range (50-100 μg/ml), leading to fluctuation
of the free fraction from 10 to 50% [122]. Moreover, sev-
eral studies revealed that there is no correlation between
therapeutic response to valproic acid and its total serum
concentration [123,124]. Meanwhile, free valproic acid
concentration has been demonstrated to have clinical
benefit in the management of epilepsy and the evasion of
unwanted side effects [125]. The significance of monitor-
ing free valproic acid in a heart transplant recipient with
hypoalbuminaemia has been shown in a case report by
Haroldson et al. After the dosing adjustment of valproic
acid was based on free concentration rather than total
concentration, the patient improved and was finally dis-
charged from the hospital [126]. A case of neurotoxicity
has been reported by Gidal et al., in which a hypoalbumi-
naemic patient exhibited a drastic increase in the plasma
free valproic acid concentration with a relatively normal
total concentration [127].
In addition, interindividual variation of total valproic
acid plasma concentration and its tendency to underrate
Figure 1 Proposed model for phenytoin binding to HSA. The
data in this report is consistent with a model in which phenytoin
has direct binding at both the warfarin-azapropazone and
tamoxifen sites, although it is possible that the competition noted
in this study could have been due to negative plus positive
allosteric effects between this drug and R-warfarin or cis-
clomiphene. From Chen et al. (2004) [99] with permission of the
authors and the publisher.
Table 3 Protein binding of antiepileptic drugs
Drug Protein
binding
Candidate for free
drug
Old generation AED
Phenobarbital 40% No
Phenytoin 90% Yes
Carbamazepine 80% Yes
Valproic acid 90-95% Yes
Primidone 15% No
Ethosuximide 0% No
New generation AED
Eslicarbazepine
acetate
30 No
Felbamate 25 No
Gabapentin 0 No
Lacosamide 15 No
Lamotrigine 55 No
Levetiracetam 0 No
Oxcarbazepine 40 No
Pregabalin 0 No
Rufinamide 30 No
Stiripentol 99 Yes
Tiagabine 96 Yes
Topiramate 15 No
Vigabatrin 0 No
Zonisamide 50 No
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advantages can be derived by depending on free valproic
acid concentration instead of total concentration in
therapeutic drug monitoring [128].
Phenytoin is a narrow therapeutic index anticonvul-
sant drug that appears to follow the Michaelis-Menten
pharmacokinetics [129,130]. Approximately 90% of
plasma phenytoin is bound to serum albumin [129].
Therapeutically, phenytoin plasma concentrations range
from 10-20 μg/ml, which is representative of the total
phenytoin concentration [131,132]. Free phenytoin was
reported by Soldin to be the most requested measure-
ment of free drug level by clinicians. It was found to be
more reliable for the prediction of phenytoin therapy
than the total concentration because only free molecules
can pass through the blood brain barrier and produce
the therapeutic effects [133].
In a retrospective study conducted in Japan by Iwa-
moto et al. [134], they investigated the relationship
between the total or free phenytoin concentration and
clinical response, as well as the factors that influence
free phenytoin concentration. The study demonstrated
that free phenytoin concentrations were poorly corre-
lated with total phenytoin concentrations in both mono-
therapy and multidrug therapy patients. Free phenytoin
concentrations were found to be strongly correlated
with the [total phenytoin]/[serum albumin] ratio in
patients receiving monotherapy. However, no significant
correlation was seen between the free phenytoin con-
centrations and the [total phenytoin]/[serum albumin]
ratio in patients receiving multidrug therapy.
Patients were classified according to their clinical
response into the following three groups: complete
response, partial response and no response. There was
no significant difference among the three groups in the
total and free phenytoin concentration in patients
receiving multidrug therapy. While the total phenytoin
concentration tended to be higher in the complete
response group than in the partial response group in
monotherapy patients, the difference was not statistically
significant. On the other hand, free phenytoin concen-
trations were significantly higher in the complete
response group than in the partial response group of
patients receiving monotherapy.
Both the mean serum albumin and the mean creati-
nine clearance were significantly lower in patients with
a high free fraction of phenytoin. However, there was
no significant correlation between creatinine clearance
and serum albumin levels. Therefore, the effect of
creatinine clearance levels on phenytoin protein bind-
ing is unrelated to the serum albumin levels. At the
same time, the mean age was significantly higher in
patients with a high free fraction of phenytoin than in
those with a normal or low free fraction. Moreover,
Banh et al. have observed that most phenytoin toxici-
ties developed in patients with normal or low total
phenytoin concentrations, but with an elevated free
concentration of phenytoin [135].
New generation antiepileptic drugs
In the last two decades, several new antiepileptic drugs
have been commercially introduced in the United States
and/or Europe. These drugs are tiagabine, eslicarbazepine
acetate, stiripentol, felbamate, rufinamide, gabapentin,
pregabalin, lacosamide, oxcarbazepine, lamotrigine, topir-
amate, levetiracetam, vigabatrin and zonisamide. It is well
documented that these newer agents exhibit better clini-
cal characteristic (i.e. less sever adverse effect and
broader therapeutic range) than the older antiepileptic
drugs. Similar to the traditional antiepileptics, some of
the newer agents may also be indicated for other clinical
situations such as chronic pain syndromes and bipolar
disorder [136-138]. Most of the newer agents show little
binding to plasma protein (Table 3) [108,139]. However,
some of the new antiepileptic drugs do not have any
affinity to plasma protein like gabapentin, levetiracetam,
pregabalin, and vigabatrin. Only two of the newer
antiepileptic drugs (i.e. tiagabine and stiripentol) are con-
sidered highly plasma protein binding [139].
Tiagabine has well documented in several observa-
tional studies and case reports to cause non-convulsive
status epilepticus [140-142]. Presently, tiagabine is rarely
used in the United States and Europe [136]. Tiagabine is
highly plasma protein binding drug (> 96%). Displace-
ment of tiagabine from its plasma protein binding sites
may occur by valproic acid, causing elevation in the free
tiagabine concentration [143]. Clinically, a reference
range of 20-200 ng/ml has been designed for tiagabine
[144]. Numerous analytical approaches are available for
the measurement of tiagabine plasma concentration
such as HPLC and GC/MS [145,146]. However, with
some assays not attaining a low enough limit of sensitiv-
ity. The measurement of free tiagabine concentration
has been a challenging problem [147].
Stiripentol is one of the new antiepileptic drugs that is
highly protein bound (>99%). It was approved in Europe
in 2001 [139]. Even though, stiripentol serum concentra-
tion of 4-22 mg/L correlates with control of absence
seizure in childhood. A clear therapeutic range for stiri-
pentol is not well-proposed [148]. Stiripentol typifies
complicated pharmacokinetic characteristics (extensive
metabolism, non-linear pharmacokinetics, and highly
plasma protein binding) similar to those of the old anti-
epileptic drugs phenytoin [149]. Attention should be
given when stiripentol is used with other antiepileptic
drugs like carbamazepine, clobazam, phenobarbital, phe-
nytoin, and valproic acid not only for the displacement
from the plasma protein, but for the inhibitory effect of
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drugs and/or metabolites as well [150,151].
Estimation of free phenytoin levels by applying
mathematical equations
Several equations were developed to estimate the free
phenytoin concentrations from the measured total phe-
nytoin concentrations and albumin concentrations. Beck
et al. investigated the reliability of different equations
for predicting free phenytoin concentrations. The
authors compared the estimated free concentrations
with the measured values. The following three equations
were involved in this study: the Gugler method, the
Sheiner-Tozer equation and the Sheiner-Tozer nomo-
gram. The results show that all three equations for esti-
mating free phenytoin concentrations were unreliable
and carried a lot of bias in predicting free phenytoin
concentrations [152]. Furthermore, use of the Sheiner-
Tozer equation was not dependable for directing ther-
apy in critically ill paediatric patients [153]. Accordingly,
direct measurement of free phenytoin concentrations is
preferred to the prediction of free phenytoin concentra-
tions using mathematical equations.
Assay techniques for free drug concentrations
The most commonly used method for measuring the
free concentration of drugs is equilibrium dialysis, in
which an appropriate buffer and a sample (containing
drug and protein) are separated by a semipermeable
membrane. At equilibrium, free drug concentration is
the same in the both chambers (in the sample compart-
ment and in the buffer compartment). After dialysis, the
total drug concentration is lower than in the early sam-
ple (due to dilution). This may lead to serious complex-
ities in the process of result interpretation, especially
when the protein binding depends on the drug concen-
tration (i.e., nonlinear binding) [154-156]. Equilibrium
dialysis is not practical for clinical implication; therefore,
ultrafiltration has become the most preferable technique
for monitoring free drug concentrations in clinical
laboratories. A small volume of serum (0.8-1.0 ml) is
centrifuged for 15-20 minutes to get the ultrafiltrates.
Then the concentrations of free drug are determined in
the protein free ultrafiltrates [108]. The length of centri-
fugation time is essential for determining free drug con-
c e n t r a t i o n .L i ue ta l .f o u n dt h a tt h e r ei sac o n s i d e r a b l e
difference between free valproic acid concentrations in
the ultrafiltrate when samples were centrifuged samples
for 5 minutes compared to 10 minutes or 20 minutes.
The authors observed that centrifugation for 5 minutes
may not be enough time to yield the actual free concen-
trations. Therefore, it is recommended to centrifuge the
specimens for at least 15 minutes [157]. McMillin et al.
reported that the volume of ultrafiltrates were directly
proportional to the centrifugation time and were inver-
sely proportional to albumin serum concentrations.
Although ultrafiltrate volume was substantially increased
with increasing centrifugation time, the free phenytoin
concentration did not change proportionately, meaning
that equilibrium was sustained between the ultrafiltrate
and serum held in the ultrafiltration device [158]. Deter-
mination of free phenytoin, valproic acid and carbama-
zepine concentrations in the ultrafiltrates can be
achieved by immunoassays [108]. Free phenytoin con-
centration in the protein free ultrafiltrate can also be
determined by liquid chromatography combined with
tandem mass spectrometry [159].
Critical analysis of lack of evidence
This review came in touch with the importance and sig-
nificance of careful monitoring of free antiepileptic
drugs concentration in patients receiving PN. However,
a clear shortage of formal research evidence was found.
The wrapping up of this article was based on several
anecdotes and case reports. Subsequently, a careful
description of the number and the type of studies were
not presented. According to the evidence-based
approach [160], case report was ranked as the lowest
source of evidence to influence the pattern of the deci-
sion makers about the therapeutic alternatives. Mostly
because these case reports and anecdotes are collected
in an unsystematic technique. So that, the outcome of
these anecdotes cannot reaches to the level of valid gen-
eralizable information [161]. Clinical practice guidelines
are developed in systematic approaches to help practi-
tioners and patients decisions about the suitable health
care for certain clinical situations [162]. In the same
time, these guidelines don’t behave as replacement for
the role of practitioners and patients in designing the
clinical judgment, but it is considered as integrating
tools, not rules. So that, the potency of anecdotes can
be realized in complex clinical decision phenomena,
when there is a limited systematic review of the litera-
ture [161].
Enkin and Jadad [163] explained the importance and
the influence of anecdotes in making clinical decision,
and Jadad [164] previously revealed the strength of the
case report within the evidence-based paradigm. When
the point is going in the same trend, anecdotes and for-
mal research evidence may support each other, and can
have an input on practice far better than could be
attained by either alone. Anecdotes can present research
findings in more meaningful approaches. It can persona-
lize, illustrate, and market the formal research findings
[163,165]. When the research evidence reveals a sense
of balance between the beneficial and adverse effects of
a treatment, or when it proposes that the treatment
alternatives are approximately equivalent, anecdotal
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decision maker can play a significant role to reach the
final decision.
In some occasions, the evidence from formal research
is not obtainable. In such scenario the decision maker
must choose whether or not there is a necessity to
explore for such evidence. Predominantly, this investiga-
tion is not ensured, because the cost or the efforts need
for further exploration might not be justified, especially
when the decisions to be made are too measly or unim-
portant. In this case anecdotes offer the most excellent
and only information on which the decision can be made.
Moreover, this anecdotal information will enhance the
motivation of the researchers to perform the necessary
formal research, and will serve as a basis to provide the
hypotheses for more definitive studies. Sometimes, it
might be difficult to implement formal studies, because
the clinical problem may be uncommon or the required
studies not are feasible or attractive to financiers [163].
Depending on what have been mentioned above, the
authors of this review used several case reports and
anecdotes as powerful tools and vehicles to motivate the
researchers to perform the necessary formal research
evidence.
Conclusions
There was no evidence supporting the existence of par-
enteral nutrition-antiepileptic drugs interaction due to
the lack of prospective, randomized, controlled trials.
However, alteration in the drug-free fraction resulting
from coadministration of PN fluids may be clinically
important and may necessitate scrupulous reassessment
of drug dosages in patients receiving these courses of
therapies. This reassessment may be particularly impera-
tive in patients with certain clinical situations in which
there are reductions in the levels of binding proteins
(e.g., burn patients). Most patients who receive PN may
also take some therapeutic drugs, leading to potential
interactions that may contribute to adverse events.
Surprisingly, there are very few published studies on the
interaction of PN fluids with therapeutic drugs, and
most of them do not focus on protein binding
[102,166-169].
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